keyword
MENU ▼
Read by QxMD icon Read
search

anti-IgE

keyword
https://www.readbyqxmd.com/read/28918644/anti-ige-and-anti-il5-biologic-therapy-in-the-treatment-of-nasal-polyposis-a-systematic-review-and-meta-analysis
#1
Alexander Rivero, Jonathan Liang
OBJECTIVE: To determine the role of biologic therapy on sinonasal symptoms and objective outcomes in chronic rhinosinusitis with nasal polyposis (CRSwNP). METHODS: PubMed, OVID MEDLINE, and Cochrane Central were reviewed from 2000 to 2015. Inclusion criteria included English-language studies containing original data on biologic therapy in CRSwNP patients with reported outcome measures. Two investigators independently reviewed all manuscripts and performed quality assessment and quantitative meta-analysis using validated tools...
September 1, 2017: Annals of Otology, Rhinology, and Laryngology
https://www.readbyqxmd.com/read/28916187/mast-cell-exosomes-can-suppress-allergic-reactions-by-binding-to-ige
#2
Guogang Xie, Haiwei Yang, Xia Peng, Lihui Lin, Juan Wang, Kun Lin, Zelin Cui, Jia Li, Hui Xiao, Yuting Liang, Li Li
Neutralizing free IgE would appear to be an important strategy for the treatment of allergic diseases. This article explores a novel anti-IgE agent.
September 12, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28910970/antibody-therapy-for-the-management-of-severe-asthma-with-eosinophilic-inflammation
#3
Ken Ohta, Hiroyuki Nagase, Maho Suzukawa, Shin Ohta
One of the characteristic features of asthma is chronic airway inflammation typically with eosinophil infiltration. Most asthmatics can be treated successfully with conventional treatment appropriate for their severity, but in some severe cases, asthma cannot be well controlled even with thorough treatment and this condition is known as 'refractory asthma'. To overcome severe refractory asthma, a new therapeutic strategy with biologics has been developed based on the knowledge of molecular mechanisms of airway inflammation in asthma, induced by the condition of high Th2-type responses and activation of eosinophils as well as allergic reactions...
July 1, 2017: International Immunology
https://www.readbyqxmd.com/read/28890861/idiopathic-anaphylaxis
#4
REVIEW
Bright I Nwaru, Sangeeta Dhami, Aziz Sheikh
Idiopathic anaphylaxis is a rare life-threatening disorder with symptoms similar to other forms of anaphylaxis. There is lack of a robust evidence base underpinning the treatment of anaphylaxis and even less so for idiopathic anaphylaxis. Much of the evidence therefore comes from relatively small case series and expert opinion. Idiopathic anaphylaxis is a diagnosis of exclusion, requiring a thorough history and careful diagnostic work-up investigating possible triggers and underlying predisposing factors. Key diagnostic tests include skin-prick testing, tests for specific-IgE, component-resolved diagnostics, and in some cases for allergen challenge tests...
2017: Current Treatment Options in Allergy
https://www.readbyqxmd.com/read/28888244/new-and-anticipated-therapies-for-severe-asthma
#5
Stephen P Peters, William W Busse
Asthma is frequently undertreated, resulting in a relatively high prevalence of patients with uncontrolled disease, characterized by the presence of symptoms and risk of adverse outcomes. Patients with uncontrolled asthma have a higher risk of morbidity and mortality, underscoring the importance of identifying uncontrolled disease and modifying management plans to improve control. Several assessment tools exist to evaluate control with various cutoff points and measures, but these tools do not reliably correlate with physiological measures and should be considered a supplement to physiological tests...
September 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28846472/the-current-state-of-food-allergy-therapeutics
#6
Meng Chen, Michael Land
The prevalence of IgE mediated food allergy is an increasing public health concern. The current standard of treatment is strict avoidance of the offending food(s). There are no FDA approved treatments for food allergy. This review will provide an overview of strategies currently under investigation for the treatment of food allergy. The main focus of research has been directed at various forms of immunotherapy, including oral, sublingual and epicutaneous delivery routes. While oral immunotherapy (OIT) has shown the greatest promise for efficacy in terms of amount of protein that can be ingested, it has also demonstrated less tolerability and a less favorable safety profile as compared to sublingual immunotherapy (SLIT) and epicutaneous immunotherapy (EPIT), which offers the least protection but has the best safety and tolerability profile...
August 28, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28833704/lipopolysaccharide-suppresses-ige-mast-cell-mediated-reactions
#7
Nianrong Wang, Melanie McKell, Andrew Dang, Amnah Yamani, Lisa Waggoner, Simone Vanoni, Taeko Noah, David Wu, Anna Kordowski, Jörg Köhl, Kasper Hoebe, Senad Divanovic, Simon P Hogan
BACKGROUND: Clinical and experimental analyses have identified a central role for IgE/FcεRI/mast cells in promoting IgE-mediated anaphylaxis. Recent data from human studies suggest that bacterial infections can alter susceptibility to anaphylaxis. OBJECTIVE: We examined the effect of LPS exposure on the induction of IgE-mast cell-(MC) mediated reactions in mice. METHODS: C57BL/6 WT, TLR-4(-/-) and IL10(-/-) mice were exposed to LPS and serum cytokines (TNF and IL-10) were measured...
August 21, 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28827590/omalizumab-efficacy-in-cases-of-chronic-spontaneous-urticaria-is-not-explained-by-the-inhibition-of-sera-activity-in-effector-cells
#8
Eva Serrano-Candelas, Rubén Martínez-Aranguren, Olga Vega, Gabriel Gastaminza, Joan Bartra, Maria Teresa Audicana, Jorge M Núñez-Córdoba, Jaime Algorta, Antonio Valero, Margarita Martin, Marta Ferrer
Omalizumab (OmAb) is a humanized anti-IgE antibody approved for the treatment of chronic spontaneous urticaria (CSU). OmAb's mechanism of action is known to include actions on free IgE and on pre-bound IgE. However, OmAb is equally and rapidly effective against autoimmune and non-autoimmune urticaria where IgE involvement is not clear, suggesting the involvement of additional mechanisms of action. In this study, we sought to investigate the ability of OmAb to inhibit mast cell and basophil degranulation induced by sera from CSU patients...
August 21, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28802100/influence-of-il-6-il-33-and-tnf-%C3%AE-on-human-mast-cell-activation-lessons-from-single-cell-analysis-by-flow-cytometry
#9
Nathalie Cop, Didier G Ebo, Chris H Bridts, Jessy Elst, Margo M Hagendorens, Christel Mertens, Margaretha A Faber, Luc S De Clerck, Vito Sabato
BACKGROUND: Mechanisms that govern priming and degranulation of human mast cells (MCs) remain elusive. Besides, most of our knowledge is based on experiments from which data only reflect an average of all stimulated cells. This study aims at investigating the effects of proinflammatory cytokines IL-6, IL-33, and TNF-α on IgE-dependent and IgE-independent activation of individual MCs. METHODS: MCs were derived from CD34(+) progenitors isolated from 50 mL whole blood from 4 healthy controls and 5 birch pollen allergic patients...
August 12, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28802075/overcoming-severe-adverse-reactions-to-venom-immunotherapy-by-using-anti-ige-antibodies-in-combination-with-a-high-maintenance-dose
#10
Eva Stretz, Eva Maria Oppel, Räwer Helen-Caroline, René Chatelain, Sebastian Mastnik, Bernhard Przybilla, Franziska Ruëff
BACKGROUND: An omalizumab treatment and a high maintenance venom dose may both help to prevent recurrent systemic allergic reactions (SAR) to venom immunotherapy (VIT). The effectiveness of this combination therapy, however, is unclear. OBJECTIVE: We wanted to explore the possibility whether a temporary treatment with the anti-IgE antibody omalizumab, combined with a VIT using an elevated maintenance dose of >100 μg venom may establish a permanent tolerance of maintenance VIT...
August 12, 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28782296/combining-anti-ige-with-oral-immunotherapy
#11
REVIEW
Chunrong Lin, Ivan T Lee, Vanitha Sampath, Chitra Dinakar, Rosemarie H DeKruyff, Lynda C Schneider, Kari C Nadeau
Food allergy is a significant medical problem that affects up to 8% of children in developed countries. At present, there are no curative therapies available in routine practice and management of food allergy involves strict allergen avoidance, education, and prompt treatment upon accidental exposure. Oral immunotherapy (OIT) is an efficacious experimental approach to food allergy and has been shown to provide a substantial benefit in terms of allergen desensitization. However, OIT is associated with high rates of allergic reactions, and the period of protection offered by OIT appears to be limited and highly variable...
August 7, 2017: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/28763192/enhancing-the-affinity-of-anti-human-%C3%AE-thrombin-15-mer-dna-aptamer-and-anti-immunoglobulin-e-aptamer-by-polyt-extension
#12
Yunlong Bai, Yapiao Li, Dapeng Zhang, Hailin Wang, Qiang Zhao
Aptamer affinity capillary electrophoresis-laser-induced fluorescence (CE-LIF) for protein detection takes advantage of aptamers for their ease of synthesis and labeling, small size, and having many negative charges. Its success relies on the high binding affinity of aptamers. One 15-mer DNA aptamer (5'-GGT TGG TGT GGT TGG-3', Apt15) shows desirable specificity for human α-thrombin, an important enzyme with multiple functions in blood. However, Apt15 has weak binding affinity, and the use of Apt15 in affinity CE-LIF analysis remains challenging...
September 5, 2017: Analytical Chemistry
https://www.readbyqxmd.com/read/28752717/justification-for-ige-as-a-therapeutic-target-in-chronic-spontaneous-urticaria
#13
M Sánchez-Borges, A Capriles-Hulet, F Caballero-Fonseca, L González-Aveledo
Monoclonal anti-IgE antibodies (omalizumab) are able to induce clinically significant benefits in patients with severe chronic spontaneous urticaria (CS). Those results led clinicians and investigators to reconsider a possible pathogenic role not previously supported for IgE and its receptors in this disease, and to investigate additional approaches for understanding its pathogenesis. IgE antibodies to unknown environmental allergens able to trigger chronic urticaria are not generally regarded as the etiologic factor for the disease...
July 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28751232/omalizumab-treatment-in-chronic-inducible-urticaria-a-systematic-review-of-published-evidence
#14
Marcus Maurer, Martin Metz, Randolf Brehler, Uwe Hillen, Thilo Jakob, Vera Mahler, Claudia Pföhler, Petra Staubach, Regina Treudler, Bettina Wedi, Markus Magerl
BACKGROUND: Omalizumab, a recombinant anti-IgE antibody, effectively treats chronic spontaneous urticaria. Evidence is lacking in chronic inducible urticarias (CIndUs), which are frequently H1-antihistamine resistant. OBJECTIVE: We aimed to determine, from the current published literature, the strength of evidence for omalizumab efficacy and safety in the treatment of CIndUs. METHODS: We performed a PubMed® search to identify evidence on omalizumab use in the following nine CIndU subtypes: symptomatic dermographism, cold urticaria, delayed pressure urticaria, solar urticaria, heat urticaria, vibratory angioedema, cholinergic urticaria, contact urticaria and aquagenic urticaria...
July 24, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28748365/urticaria-and-angioedema-an-update-on-classification-and-pathogenesis
#15
REVIEW
Susanne Radonjic-Hoesli, Kathrin Scherer Hofmeier, Sara Micaletto, Peter Schmid-Grendelmeier, Andreas Bircher, Dagmar Simon
Urticaria is a common, mast cell-driven disease presenting with wheals or angioedema or both. In the last years, urticaria has increasingly attracted notice to clinicians and researchers, last but not least inspired by the approval of omalizumab, an anti-IgE antibody, for urticaria treatment. There is wide consensus on the clinical classification based on duration and elicitation. However, the pathogenesis is incompletely understood. This review summarizes current guidelines for the management and novel insights in the pathogenesis of urticaria with special focus on their impact on clinical praxis...
July 26, 2017: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/28734860/the-expanding-field-of-biologics-in-the-management-of-chronic-urticaria
#16
Shyam Joshi, David A Khan
Chronic urticaria (CU) is the occurrence of urticaria with or without angioedema for at least 6 weeks. Management has traditionally involved antihistamines as first-line therapy with various alternative therapies for refractory cases. Largely based on the success of biologics for various diseases, this class of drugs has come to the forefront of medical research. The first and only Food and Drug Administration-approved biologic for the management of CU is omalizumab (humanized anti-IgE mAb). In the past decade, a substantial amount of research has been centered on the mechanism of action, efficacy, dosing, and safety of omalizumab...
July 19, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28721017/targeted-therapy-in-severe-asthma-today-focus-on-immunoglobulin-e
#17
REVIEW
Girolamo Pelaia, Giorgio Walter Canonica, Andrea Matucci, Rossella Paolini, Massimo Triggiani, Pierluigi Paggiaro
Asthma is a complex chronic inflammatory disease of multifactorial etiology. International guidelines increasingly recognize that a standard "one size fits all" approach is no longer an effective approach to achieve optimal treatment outcomes, and a number of disease phenotypes have been proposed for asthma, which has the potential to guide treatment decisions. Among the many asthma phenotypes, allergic asthma represents the widest and most easily recognized asthma phenotype, present in up to two-thirds of adults with asthma...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28696863/update-on-oral-immunotherapy-for-egg-allergy
#18
François Graham, Natacha Tardio, Louis Paradis, Anne Des Roches, Philippe Bégin
Oral immunotherapy (OIT) is an emerging treatment for IgE-mediated egg allergy. In the past decade, a multitude of studies have assessed the potential for egg OIT to induce clinical desensitization. The following review will evaluate the efficacy and safety of this therapy as determined by randomized controlled, non-randomized controlled and uncontrolled trials. Recent studies using reduced allergenic egg products and anti-IgE assisted therapy to improve egg OIT safety will also be discussed. Recent advances in the mechanisms underlying food OIT suggest that certain immune parameters may be helpful in monitoring response to therapy, including egg OIT...
July 11, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28696336/perspectives-on-exhaled-nitric-oxide
#19
Fabio Luigi Massimo Ricciardolo, Philip E Silkoff
The history of nitric oxide (NO) in respiratory field dates back to the beginning of '90s with the ancestral study by Lars Gustafsson et al. describing the presence of endogenous NO in the exhaled breath of human beings. Soon after, independent studies showed that exhaled NO concentrations (FENO) is higher in asthmatics than in normal subjects. Not all asthmatics demonstrate a high FENO reflecting heterogeneity of asthma. High values of FENO are associated with over-expression of corticosteroid-sensitive iNOS isoform and allergic/eosinophilic inflammation...
July 11, 2017: Journal of Breath Research
https://www.readbyqxmd.com/read/28691309/serial-d-dimer-plasma-levels-in-a-patient-with-chronic-spontaneous-urticaria-developing-resistance-to-omalizumab
#20
R Asero
Chronic spontaneous urticaria (CSU) is a condition presenting as the spontaneous occurrence of itchy weals with or without angio-oedema for > 6 weeks. A patient with severe chronic spontaneous urticaria who developed resistance to omalizumab is described. The patient's D-dimer plasma levels strictly paralleled the disease activity despite the administration of anti-IgE therapy.
July 10, 2017: Clinical and Experimental Dermatology
keyword
keyword
41626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"